S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions

Skechers Stock Looks Ready To Breakout

Skechers Stock Looks Ready To BreakoutWith a 7% jump on Monday, shares of Skechers (NYSE: SKX) came within a few dollars of breaking out a long-term range. The iconic shoemaker has watched its shares rally more than 140% in the past year as they’ve undone the damage from last year’s pandemic-induced crash, dollar by dollar. Current signs suggest this recovery has room to keeping running yet.

Technically minded investors would do well to keep an eye on them as they approach the double top resistance around the $44 mark, where shares were turned back in 2018 and 2019. Unlike the prior rallies that took shares to that point in the past, this march higher has had a consistent look of strength about it, versus erratic jumps higher.

Fresh Price Target

Only last month UBS were out with a strong bull call on Skechers stock and upped their price target to $52. Even with the fresh highs seen since then, that’s still suggesting upside of some 25% from last night’s closing price. With the technical setup likely to be flagged on every indicator engine on Main Street, you can be sure that there are plenty of eyes watching to see what the shares will do as they close in on $44.

UBS analyst Jay Sole is particularly bullish on the company’s ability to make the most of the ongoing economic reopening. In a note to clients he said "Skechers’ 4Q report was neutral for the stock price as the company's near-term margin commentary weighed on sentiment. However, the current market environment remains very forgiving, in our view. We think the market will very soon revisit this stock and see reset FY21 expectations, a business which will improve sequentially throughout CY21, a relatively inexpensive looking valuation, and decide Skechers is still a good reopening stock."


This Q4 report, from early February, had revenue effectively flat on the year which maybe wasn’t the worst result all things considered. To be fair, this isn’t a tech stock we’re talking about but a fairly stolid consumer name that’s fighting hard to get into the 21st century.

Solid Reputation

Unlike the likes of Nike (NYSE: NKE) who have a bit of flash and dazzle about them, Skechers has stayed away from high profile sports sponsorship deals or partnerships with Apple (NASDAQ: AAPL). Instead they’ve focused on building out a solid position in the market for themselves with the reputation for dependable, comfortable shoes that mightn’t be the most stylish or fashionable but get the job done.

They developed a solid track record of growing revenue and EBITDA year over year through last January, and will be forgiven for not keeping that record going through the COVID pandemic. But with the world’s economies closer to getting back to normal than they’ve been yet, odds are Skechers’ management team will be keen to get back to normal operating procedure too. That means consistent results that should flow through to a well-performing stock price.

If shares can maintain their current momentum and test the double top highs of $44 in the next few sessions, it should get interesting. At worst they’ll retreat before likely consolidating for another attempt, a great entry point to consider, or they’ll smash through and leave it behind them as fresh support. Either way it's worth getting SKX onto your watchlist and keeping an eye on it in the coming weeks.

Skechers Stock Looks Ready To Breakout

Should you invest $1,000 in Skechers U.S.A. right now?

Before you consider Skechers U.S.A., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Skechers U.S.A. wasn't on the list.

While Skechers U.S.A. currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Skechers U.S.A. (SKX)
2.7289 of 5 stars
$57.11+2.0%N/A16.75Moderate Buy$59.33
NIKE (NKE)
2.9889 of 5 stars
$107.96+0.3%1.26%33.32Moderate Buy$122.17
Apple (AAPL)
2.5565 of 5 stars
$189.79-0.1%0.51%31.01Moderate Buy$198.25
Compare These Stocks  Add These Stocks to My Watchlist 

Sam Quirke

About Sam Quirke

  • s.quirke.us@gmail.com

Contributing Author

Technical Analysis

Experience

Sam has been a contributing writer for MarketBeat since 2019.

Areas of Expertise

Technical and fundamental analysis, tech stocks, large caps, timing entries and exits

Education

Trinity College, Dublin, Ireland

Past Experience

Professional futures trader, start-up fund manager


Featured Articles and Offers

Opportunities in September for These 3 Growth Stocks

Opportunities in September for These 3 Growth Stocks

In this video, we look at three growth stocks that offer a buying opportunity in September. American Express, Amgen, and Apple.

Search Headlines:

My Account -